Group
Biotech
10 themes86 tickers
10D rank#19of 129 groups
Dive into Biotech, where we explore everything from established pharma giants and cutting-edge GLP-1 therapies to revolutionary oncology, genetic medicine, and AI-driven drug discovery. Understand what's going on in health innovation!
Biotech '24: GLP1+46.67%10.0%
Biotech '24: Oncology+43.38%10.0%
Biotech '24: Pharma/Therapeutics+41.38%10.0%
Biotech '25: Commercial / Late Stage+34.75%10.0%
Biotech '25: Neurology, CNS & Rare Disorders+48.82%10.0%
Biotech '25: Oncology & Immunotherapy+102.63%10.0%
Biotech '25: RNA-Based/Genetic Medicine+163.98%10.0%
Biotech '26: AI Driven Drug Discovery+65.87%10.0%
Biotech '26: Established Pharma+28.71%10.0%
Biotech '26: Scalable Oncology Drugs+69.67%10.0%
As of Jul 10, 2026, 7:14 AM ET
Themes in this group
Build 20260710T074722
| Biotech '24: GLP1 | 4 | $8.82B | $35.26B | +1.06% | +1.12% | +5.92% | +6.84% | +1.93% | +44.90% | +11.00% | +194.89% | +7.21% | +59.13% | +7.86% | +19.05% |
| Biotech '24: Pharma/Therapeutics | 13 | $3.67B | $47.74B | +0.05% | +0.13% | +5.50% | +5.29% | +9.70% | +41.25% | +76.06% | +4.42% | +7.20% | +83.56% | +1.68% | +24.95% |
| Biotech '26: Scalable Oncology Drugs | 12 | $18.08B | $216.92B | -0.26% | +0.19% | +5.22% | +4.03% | +20.08% | +69.12% | +86.37% | +15.16% | +21.33% | +87.81% | +0.46% | +8.60% |
| Biotech '25: Oncology & Immunotherapy | 12 | $6.55B | $78.56B | -1.31% | +0.37% | +4.71% | +4.19% | +32.01% | +102.23% | +128.34% | +79.04% | +29.48% | +136.34% | -1.36% | +26.14% |
| Biotech '25: Neurology, CNS & Rare Disorders | 7 | $1.47B | $10.29B | -0.63% | +0.23% | +4.10% | +2.05% | +16.44% | +56.01% | +68.72% | +39.44% | +11.71% | +109.21% | +1.50% | +6.17% |
| Biotech '24: Oncology | 8 | $3.54B | $28.33B | -1.22% | -0.32% | +3.19% | +1.84% | +17.28% | +41.76% | +21.86% | -9.24% | +2.02% | +67.03% | +9.67% | +17.13% |
| Biotech '26: Established Pharma | 10 | $183.26B | $1.83T | -0.28% | +0.21% | +2.19% | +2.62% | +11.08% | +30.39% | +30.87% | +54.17% | +4.06% | +33.69% | +0.45% | +5.08% |
| Biotech '25: RNA-Based/Genetic Medicine | 7 | $4.83B | $33.79B | +1.25% | -0.97% | +1.99% | +2.97% | +55.44% | +169.33% | +36.63% | +8.43% | +38.83% | +288.86% | -2.43% | +20.46% |
| Biotech '25: Commercial / Late Stage | 5 | $5.32B | $26.61B | +0.61% | -0.50% | +0.02% | +3.38% | -1.62% | +32.29% | +46.73% | +11.28% | +6.33% | +33.01% | +7.27% | +16.13% |
| Biotech '26: AI Driven Drug Discovery | 18 | $87.88B | $1.58T | +0.78% | +3.69% | -0.00% | +0.21% | +42.32% | +65.84% | +89.59% | +127.43% | +33.19% | +86.31% | +8.15% | +23.24% |
Default: 10D ↓ · Click headers to sort · Shift+click secondary